rc 3095 has been researched along with Ache in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cancella, A; da Rocha, AB; De Nucci, G; DiLeone, LP; Horowitz, M; Pereira, AS; Pohlmann, P; Richter, M; Schunemann, D; Schwartsmann, G; Souza, F; Souza, FH | 1 |
1 trial(s) available for rc 3095 and Ache
| Article | Year |
|---|---|
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bombesin; Female; Gastrin-Releasing Peptide; Gastrins; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Pain; Peptide Fragments; Skin | 2006 |